NCT06319313尚未招募2 期
A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC
Shanghai JMT-Bio Inc.0 个研究点目标入组 534 人开始时间: 2024年5月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 534
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ranged from 18 to 75 years old (inclusive), regardless of gender;
- •Pathological diagnosis as sqNSCLC, with EGFR highly expressed, without other driver genes
- •Tumor tissue available for central laboratory testing;
- •Disease progression after prior anti PD-1/PD-L1 and platinum containing chemotherapy
- •Measurable disease according to RECIST1.1;
- •Eastern Cooperative Oncology Group (ECOG) score 0-1 points;
- •Life expectancy ≥3 months
- •Adequate main organs and bone marrow function.
- •Patients must give informed consent to this study before the experiment and voluntarily sign a written informed consent form.
排除标准
- •Previously used anti EGFR, or docetaxel;
- •Central nervous system metastasis or meningeal metastasis;
- •Patients with high risk of bleeding due to tumor invasion of important arteries;
- •Uncontrolled or requiring repeated drainage of pleural effusion, pericardial effusion, or abdominal effusion;
- •The adverse reactions of previous anti-tumor treatments (including radiotherapy) have not yet recovered to CTCAE 5.0 evaluation ≤ level 1 except for toxicity such as alocepia or fatigue, which is judged to be of no safety risk by researchers;
- •Diagnosed as a second primary malignant tumor (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ and breast carcinoma in situ, etc.) within 5 years prior to the first administration of the study drug;
- •Have received anti-tumor treatments such as systemic chemotherapy, biological therapy, immunotherapy, radical radiotherapy chemotherapy, etc. within 28 days before the first dose of the study drug;
- •Have undergone major surgery (excluding needle biopsy) or suffered severe traumatic injury within 28 days before the first dose of study drug;
- •Have received a live viral vaccine or live-attenuated vaccine within 28 days before the first dose of study drug or plan to receive it during the study;
- •Have received palliative radiotherapy, small molecule targeted therapy, immunomodulatory drugs, NMPA approved modern traditional Chinese medicine preparations and other anti-tumor treatments, within 14 days before the first dose of study drug;
- •Those who use strong CYP3A4 inducers within 14 days before the first administration of the study drug, or those who use strong CYP3A4 inhibitors within 1 week, or those who cannot suspend the use of the above drugs during the study;
- •Have a history of serious cardiovascular disease;
- •Have a history of serious lung disease;
- •History of autoimmune diseases;
- •History of immunodeficiency
- •A history of gastrointestinal perforation and/or fistula within 6 months, or gastrointestinal obstruction and active inflammatory bowel disease within 28 days prior to the first study drug administration
- •Have infectious diseases requiring systemic anti-infective treatment;
- •Active hepatitis B; hepatitis C infection; syphilis infection, active tuberculosis;
- •Known hypersensitivity or intolerance to any component of EGFR monoclonal antibody, human serum albumin, docetaxel, and its excipients; Individuals known to be allergic and/or contraindicated to glucocorticoids
- •Women during lactation or pregnancy;
- •Any male and female patients with fertility who refuse to use effective contraceptive methods throughout the entire trial period and within six months after the last administration;
- •Other conditions that, in the opinion of the investigator, may affect the safety or compliance of drug treatment in this study, including but not limited to: psychiatric disorders, any severe or uncontrollable diseases, etc.
研究组 & 干预措施
JMT101+ docetaxel
Experimental
干预措施: JMT101 (Drug)
JMT101+ docetaxel
Experimental
干预措施: docetaxel (Drug)
JMT101+HB1801
Experimental
干预措施: JMT101 (Drug)
JMT101+HB1801
Experimental
干预措施: HB1801 (Drug)
HB1801
Experimental
干预措施: HB1801 (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: Up to approximately 2 years
Overall Survival (OS)
时间窗: Up to approximately 3 years
Incidence and severity of adverse events (AE) and serious adverse events (SAE)
时间窗: Up to approximately 3 years
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.
次要结局
- Progression-free Survival (PFS)(Up to approximately 2 years)
- Disease Control Rate (DCR)(Up to approximately 2 years)
- Duration of response（DOR）(Up to approximately 2 years)
- JMT101 Concentrations in Plasma(Up to approximately 2 years)
- Total and Free Docetaxel Concentrations in Plasma(Up to approximately 2 years)
研究者
相似试验
终止
2 期
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial PneumoniaCommunity-acquired Bacterial PneumoniaNCT02605122Melinta Therapeutics, Inc.97
尚未招募
2 期
A Study of JMT101 in Patients With Metastatic Colorectal CancerMetastatic Colorectal Cancer (mCRC)NCT06089330Shanghai JMT-Bio Inc.102
Unknown
2 期
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsBiliary Tract CancerNCT03873532Hutchison Medipharma Limited298
终止
2 期
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsHER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsNCT06516926Jiangsu HengRui Medicine Co., Ltd.11
已完成
2 期
Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI PatientsDiabetic Foot InfectionDiabetic FootNCT05174806Microbion Corporation47